Introduction
There is strong evidence that gene expression can be affected by changes in chromatin structure and the association of DNA with nucleosomes. The acetylation of lysine residues on histone tails by histone acetyltransferases (HATs) neutralizes their charge and decreases the affinity of histones for DNA, facilitating transcription of these regions. Conversely, the deacetylation of these residues by histone deacetylases (HDACs) restores this affinity and can decrease the accessibility of DNA to transcriptional machinery (Struhl, 1998) . In addition, chromatin structure can be affected by other post-translational modifications of histone proteins, such as methylation (Bannister et al., 2001) . Finally, the Swi/Snf class of proteins can form complexes that can profoundly effect chromatin structure and gene expression (Sudarsanam and Winston, 2000) . Genetic and biochemical studies have demonstrated that these Swi/Snf proteins can cause ATPdependent disruption of nucleosome structure at a promoter, and enhance the binding of transcription factors to their binding sites (Sudarsanam and Winston, 2000) . The action of these proteins can also lead to nucleosome movement and changes in chromatin conformation, resulting in profound transcriptional activation (or repression) of a gene or region.
Chromodomain, helicase, DNA-binding (CHD) genes (Woodage et al., 1997) encode a novel class of Swi/Snf proteins that contains not only an Swi/Snf-like helicaseATPase domain, but also contains additional functional domains. These proteins have a DNA-binding domain as well as a chromodomain motif that can directly effect chromatin structure and gene transcription. There are currently four known members of this gene family in humans (CHD1-CHD4) (Woodage et al., 1997) , two of which have been shown to participate in multiprotein complexes responsible for chromatin remodeling. The (nucleosome remodeling and histone deacetylation (NuRD) complex (originally known as Mi2 in Drosophila) is an B2 MDa complex that consists of at least seven proteins, but the key functional protein in these complexes is either Mi-2a or Mi-2b (now known as Chd3 and Chd4, respectively). There is increasing evidence that Chd protein complexes can have a profound effect on chromatin structure and gene expression, and so they are likely to play an important role in regulating development, cell cycle control, and oncogenesis.
In the process of mapping the commonly deleted region of 1p36.3 in human neuroblastomas White et al., 1997; Hogarty et al., 2000; Maris et al., 2001) , we have encountered a novel member of the CHD gene family. This gene, called CHD5, has chromodomain, helicase, and DNA-binding motifs most similar to CHD3 and CHD4. Furthermore, this gene is preferentially expressed in the total brain, fetal brain, and cerebellum, as well as in the adrenal gland. Finally, expression is virtually absent in neuroblastoma cell lines, and very low in primary neuroblastomas with 1p36 deletion and other adverse features. We propose that this gene is a new member of this important gene family, and it may play a role in normal neural development and possibly in neoplasia.
Results

Identification of CHD5 within 1p36.3
We had previously established that PACs RPCI-11-120G22 and RPCI-11-233K16 lie within a region of 1p36.3 consistently deleted in primary human neuroblastomas (Hogarty et al., 2000; White et al., 2001) . The complete DNA sequence of these two clones was subsequently determined in collaboration with the Sanger Institute (Bentley et al., 2001; White et al., 2001) , and the sequences were shown to partially overlap. Gene prediction algorithm analysis of this sequence contig predicted a large, multiexonic gene spanning portions of both cloned sequences. The 3 0 half demonstrated nearly perfect homology to the entire reported sequence of two partial cDNAs (KIAA0444/ AB007913 and DKFZp434N231/AL117491) in GenBank. In addition, the 3 0 end matched the consensus sequence of a cluster of 60 expressed sequence tags (ESTs) (UniGene EST cluster Hs.158291; http://www. ncbi.nlm.nih.gov/UniGene), strongly suggesting that this was an authentic transcript. The UniGene cluster record indicated strong paralogy to members of the CHD family of chromatin structure regulators (see below), so we named the gene CHD5. Homologous cDNA sequences in mouse, rat, and chicken, as well as Xenopus laevus, Arabidopsis, Drosophila melanogaster, Caenorhabditis elegans, Plasmodium falciparum, Saccharomyces cerevisiae and S. pombe were also apparent, indicating that this gene or its parent gene family was highly conserved in eukaryotes. We have submitted the complete annotated sequence to GenBank (accession # AF25231). An automated annotation of genomic sequence subsequently identified partial sequence of this chromodomain gene (XP_030999), based on our submission.
CHD5 genomic structure
We determined that CHD5 consists of 42 exons spanning 78218 bp of genomic DNA (Table 1, Figure 1 ). The exon lengths range from 54 (exon 41) to 3635 bp (exon 42), and the largest exon entirely within the coding region was 239 bp (exon 5). The putative initiating AUG is within exon 1, and the last exon contains the entire 3 0 UTR. The introns range in size from 85 bp (intron 5) to 11 667 bp (intron 1). The two PHD domains span portions of exons 8-9 and 9-10, the two chromodomains are contained within exons 10 and 11-12, and the SNF2 and helicase domains span exons 14-19 and 21-23, respectively. Thus, all six domain structures are confined to the central 16 of the 41 coding exons. Strong homology to other CHD family members outside of these domains suggests the presence of additional functional elements (Figure 2 ) elsewhere in the protein. We have found no evidence for other transcripts contained within any of the CHD5 introns, although we cannot entirely rule out this possibility.
CHD5 is physically juxtaposed to two previously characterized genes. The ribosomal protein RPL22 is aligned tail-to-head with CHD5, and 6.4 kb separate the 3 0 end of RPL22 and the transcriptional start of CHD5. The 3 0 end of CHD5 is aligned tail-to-tail with the potassium channel KCNAB2, with the two transcriptional ends separated by 1.3 kb. This configuration makes it unlikely that CHD5 shares transcriptional regulation with its nearest neighbors. A 200-kb window encompassing CHD5 has a GC content of 55.2%, indicating that CHD5 is likely within a gene-rich region. Analysis of the CHD5 genomic sequence identified a CpG island starting 630 bp 5 0 to the transcriptional start and containing all of exon 1 as well as the initial 680 bp of intron 1.
Because gene prediction algorithms have difficulty precisely predicting large genes, we compared the experimentally determined genomic structure with the predictions from Genscan and Ensembl. Three evaluations were used: exon sensitivity (% of exons identified at least in part), exon specificity (% of exons predicted that are true exons), and exon identity (% of actual exons that were perfectly predicted positionally). Genscan had a sensitivity of 98%, a specificity of 93%, and an exon identity of 81%, while Ensembl had a sensitivity of 84%, a specificity of 100%, and an exon identity of 74%.
CHD5 mRNA analysis
The predicted CHD5 sequence extended 3.0 and 1.8 kb 5 0 of the reported partial cDNA sequences AB007913 and AL117491, respectively. RT-PCR of fetal brain mRNA using a series of primers from predicted exons that were increasingly 5 0 to the reported cDNAs resulted in recovery of the entire 5 0 coding region. (Figure 1 ). The transcribed sequence has a GC content of 60.1%, and several local stretches (especially the 5 0 -most portion) exceed 80% in GC content. A number of consensus transcription factor binding sites, including several Sp1, GCF, and APfamily sites, are present just upstream of and within the 5 0 UTR. The initiator AUG has been designated at mRNA position 101, based on comparison to the start sites in CHD3 and CHD4, and is preceded by an inframe stop codon at bp 38. Although the context of this AUG does not match the Kozak consensus perfectly (Kozak, 2000) , alternative downstream AUGs at positions 155 and 171 are poorer matches. Thus, some uncertainty remains regarding the true initiating codon. A consensus polyadenylation signal (AATAAA) is present 14 bp before the transcriptional 3 0 terminus. No known repetitive elements are present in the 3 0 UTR or elsewhere in the transcribed sequence, although the surrounding genomic region is both LINE and SINErich.
Chd5 protein analysis
Next, we performed sequence analysis of the Chd5 protein sequence predicted from the cDNA open reading frame. The Chd5 open reading frame predicts a protein of 1954 residues. The 5 0 portion of Chd5 is predicted to contain two zinc-fingers of the PHD class (amino-acid positions 345-390 and 418-463), followed closely by two chromodomains (510-525 and 596-625) . PHD zinc-finger motifs are thought to play roles in chromatin-associated transcriptional regulation, whereas chromodomains are frequently observed in proteins involved in recruitment of transcriptional regulatory complexes. The central portion of the protein 50-67, 54-71, 97-114, 100-117, 240-257, 253-270, 918-935) .
Sequence comparison to other Chd family members
The extent of amino-acid identity and similarity between HsChd5 and other Chd proteins are as follows: HsChd1, 25.4% identity (38.6% similarity); HsChd2, 27.1% (41.0%); HsChd3, 70.0% (80.2%); and HsChd4, 75.5% (84.4%). In addition, HsChd5 is strikingly homologous to its ortholog in Drosophila, dMi-2 (55.0% identity, 67.8% similarity). Moreover, sequences homologous to Chd5 have been found in a number of other metazoans (see above), whereas the SNF2 and helicase regions of Chd5 show considerable homology to a number of proteins from bacterial and archael species. Although all the genes that comprise the CHD family share homology in the conserved functional domains (chromodomain, DNA helicase/ATPase domain and DNA-binding domain), HsChd5 has stronger homology with HsChd3, HsChd4, and with dMi-2 than it does with HsChd1 or HsChd2. As shown in Figure 2 , the main functional difference between the Chd3/4/5 class (which includes dMi-2) and the Chd1/2 class is that only the former possesses PHD zinc-finger domains. HsChd5 shares the same number and order of functional domains with the other Chd3/4/ 5 class members. Moreover, long blocks of X90% Chd3/4/5 class-specific homology outside of the characterized functional domains (residues 174-203, 1254-1327, 1403-1422, 1431-1492, 1541-1647, 1887-1910, 1919-1946, 1963-1997, and 2015-2066 in Figure 1 ) are striking, indicating the likely presence of additional functional motifs. The majority of these putative motifs show homology only to characterized Chd family proteins. Chd5 significantly diverges from both Chd3 and Chd4 only in a few regions: a 34 amino-acid Chd5-specific insertion following the helicase domain (residues 1334-1367 in Figure 1 ), a region of divergence stretching approximately 170 amino acids (residues 1668-1886 in Figure 1) , and a unique 50-residue C-terminus. Since other members of this class are known to be components of the NuRD complex (Tong et al., 1998; Xue et al., 1998) , it seems likely that Chd5 can also form a functional NuRD complex. The predicted mouse ortholog (MmChd5) has a high degree of protein sequence homology with HsChd5 (93.0% identity, 96.0% similarity; data not shown), which extends beyond the functional domains (although the sequence of the mouse ortheolog is incomplete).
Tissue expression profile
Over 90% of the CHD5-associated ESTs in dbEST were derived from cDNA libraries of either brain or neuralderived tissues (as well as pancreas and testis). Accessible serial analysis of gene expression (SAGE) data at the NCBI confirmed the neural-specific expression pattern, with colon, prostate, pancreas, and solid tumors derived from a variety of tissues, all demonstrating expression of the gene. To more precisely determine the expression profile of CHD5, real-time quantitative RT-PCR was performed on a panel of 18 normal tissue RNAs using a pair of CHD5 cDNA-specific primers. Detectable expression of CHD5 was limited to all neural-derived tissues (fetal brain, total brain, cerebellum) and adrenal gland (Figure 3a) , with no expression detected in placenta, liver, fetal liver, spleen, bone marrow, thyroid, thymus, salivary gland, stomach, pancreas, small intestine, colon, or prostate. Comparable results were obtained independently using a semiquantitative, gel-based RT-PCR assay for CHD5 (data not shown) (Eggert et al., 2000) . Interestingly, the adrenal gland is a common site for the origin of neuroblastomas (see below).
Expression in neuroblastoma cell lines
Expression of CHD5 was also analysed by real-time RT-PCR in a panel of 24 neuroblastoma cell lines. A fetal brain sample was included for comparison with normal tissue expression. All cell lines had absent or dramatically lower levels of gene expression relative to fetal brain (Figure 3b 
Expression in primary neuroblastomas
Finally, we examined the expression of CHD5 in a representative panel of 137 primary neuroblastomas using real-time RT-PCR (Figure 4 ). Low expression was strongly correlated with 1p loss (P ¼ 0.001), MYCN amplification (Po0.001), advanced clinical stage (P ¼ 0.001), and unfavorable histology (P ¼ 0.02), but not with older age (P ¼ 0.3). Since all of these features are associated with a worse outcome, these finding suggest that low CHD5 expression may contribute to the unfavorable outcome seen in patients with these highrisk features. We examined the gene for mutations using simple sequence conformation polymorphism (SSCP) analysis, with sequence confirmation, and only a single missense mutation was identified, suggesting that mutation is not a common mechanism of inactivation.
Discussion
In the process of characterizing genes that map to a region of frequent deletion on 1p36.3 in neuroblastomas, we encountered CHD5, which encodes a protein with homology to previously identified chromodomain proteins. Chd1 was first identified in 1993 as a mammalian DNA-binding protein that contained a chromodomain and an SNF2/SWI2-like helicase domain (Delmas et al., 1993) . Chd2 was identified based on its homology to Chd1, but a unique role for this protein has not been identified (Woodage et al., 1997) . Chd3 and Chd4 were first identified as autoantigens in patients with dermatomyositis (Ge et al., 1995; Seelig et al., 1995; Zhang et al., 1998) and were subsequently found to be members of the CHD gene family. These two proteins are critical to the function of multiprotein chromatin remodeling (NuRD) complexes. There are two major histone deacetylase complexes in mammalian cells. One is called NuRD (Xue et al., 1998) and the other is called Sin3 or SAP (for Sin3 associated protein) complex (Ahringer, 2000) . Both of these complexes share four proteins -two histone deacetylases (HDAC1 and HDAC2) and two Rb-associated histonebinding proteins (RbAp46 and RbAp48). The defining protein of the NuRD complexes is a chromodomain protein of the Chd family (Chd3 or Chd4). In addition, NuRD complexes are consistently associated with at least two other proteins, called metastasis-associated protein 1 (MTA1, or MTA2) and methyl DNA-binding domain protein 3 (MBD3) (Ahringer, 2000) . The other major type of HDAC complex is defined by the Sin3A or B proteins, which are the defining proteins for this complex. The SAP contains at least two other unique proteins, known as SAP18 and SAP30 (Ahringer, 2000) . Although their function is unknown, at least SAP30 may facilitate the association of the SAP with other proteins such as transcription factors. These complexes are involved in chromatin remodeling, and then binding most likely facilitate transcriptional repression.
All of the Chd proteins have two chromodomains toward the N-terminal third of the protein. There is also a large SWI/SNF-like helicase/ATPase domain in the middle third. Swi/Snf proteins were initially identified in yeast as playing a role in mating type switching or sucrose metabolism, but they were subsequently found to have roles in chromatin remodeling. All the Chd proteins also have a DNA-binding region at the Cterminus of the protein, but Chd1 and Chd2 are similar to each other, whereas they are somewhat less homologous to Chd3, Chd4, and Chd5, which are similar to each other. In addition, the latter group also shares two PHD domains that are N-terminal to the chromodomains that are not found in Chd1 and Chd2. Owing to its homology to Chd3 and Chd4, Chd5 likely functions as part of an NuRD histone deacetylase complex. The Chd5 protein sequence is virtually identical to the partial sequence available for mouse Chd5 (93% identity, 96% similarity). Surprisingly, human Chd5 has 67.8% similarity to dMi-2, showing striking conservation of this protein over considerable evolutionary distance. Chromodomain proteins can affect gene expression in a developmentally restricted and gene-specific manner. The Chd protein complexes likely confer the specificity of their transcriptional repression through the recruitment of other effector proteins with which they interact. These proteins may then bind to the promoters of other genes and target histone deacetylation and transcriptional repression to these genes or chromatin regions. For example, Polycomb group (PcG) proteins maintain repression of HOX genes during development in Drosophila, and this transcriptional repression is sitespecific (Muller, 1995; Kehle et al., 1998) . Hunchback (Hb) also binds directly to HOX regulatory sequences and represses transcription. Interestingly, the transcriptional repression imposed by both PcG and Hb is mediated by the binding of dMi-2, a Chd homolog (Kehle et al., 1998) . Furthermore, during embryonic CNS development in Drosophila, the sequential expression in neuroblasts of four proteins, including Hb, identifies a transcription factor network regulating the temporal development of all ganglia (Muller, 1995) . This is a clear example of a chromodomain protein controlling the regulation of a small number of genes important in neural development.
We analysed the expression pattern of CHD5 in a variety of tissues by a quantitative real-time RT-PCR technique, and expression was higher in brain than in most other tissues by at least 2 orders of magnitude. We next examined neural tissues in some detail, and the highest levels were found in total brain, fetal brain, and cerebellum, followed by spinal cord and adrenal gland. This exclusive expression in the brain and in neural tissues, and the putative chromodomain function, suggests that CHD5 may play an important role in the development of the nervous system.
There is a microdeletion syndrome involving 1p36.3 that leads to a variety of congenital and developmental anomalies (Slavotinek et al., 1999) . Many of these deletions would include the region in which CHD5 is encoded, and so haploinsufficiency of CHD5 may contribute to the neurological and developmental abnormalities frequently encountered with these patients (Wu et al., 1999) . Further analysis will be required to determine if CHD5 is consistently involved in these deletions and correlates with a particular phenotype. Genes involved in chromatin remodeling play an important role in neoplasia. There are several cancerspecific rearrangements that have been shown recently to involve chromatin-remodeling genes. Acute promyelocytic leukemia (APL) results from translocations between the RARa gene on chromosome 17 and either the PML gene on chromosome 15 or the PLZF gene on chromosome 11 (Grignani et al., 1998; Lin et al., 1998; Kitamura et al., 2000) . These chimeric transcription factors interact with the SAP histone deacetylase complex, and differences in these interactions may account for the different responses of APML with these two translocations to retinoid therapy. Retinoic acid can cause the release of the SAP complex from the RARa/ PML complex, whereas it cannot cause dissociation in RARa/PLZF. BRG1, a gene encoding a component of the Swi/Snf complex, has been implicated in growth control through its interaction with pRb, and Brg1 may be a negative regulator of proliferation. BRG1 has been shown recently to be mutated in multiple tumor cell lines, and reintroduction of this gene can reverse the transformed phenotype (Wong et al., 2000) . In addition to pRb (Brehm et al., 1998; Luo et al., 1998; MagnaghiJaulin et al., 1998) , chromatin remodeling proteins and complexes have been shown to interact with several other proteins involved in human neoplasia, such as the breast cancer protein BrCa1 (Yarden and Brody, 1999) , Myc networking proteins of the Mad family (Mad, Mxi1) (Schreiber-Agus et al., 1995; Ayer et al 1995; Harper et al., 1996; Kasten et al., 1996; Schreiber-Agus and DePinho, 1998) , the DNA replication checkpoint gene ATR (Schmidt and Schreiber, 1999) , and the HPV-E7 protein (Brehm et al., 1999) . These data strongly suggest that alterations of gene expression mediated through chromatin remodeling may be critical for tumorigenesis in a variety of cancers.
CHD5 maps to a region that is frequently deleted in neuroblastomas and other neural crest tumors, so deletion of CHD5 may contribute to malignant transformation. Indeed, assuming that Chd5 participates in an NuRD-type chromatin-remodeling complex, the loss of expression of this gene and protein may prevent normal neuronal maturation of developing neuroblasts. This complex may inactivate proliferation-associated genes in neural tissues, and so loss of expression would leave these cells in a growth mode and possibly prevent differentiation. Neuroblastomas are tumors of sympathetic neurons and commonly arise in the adrenal medulla (as well as the sympathetic chain). Therefore, the pattern of expression in developing neural tissues (brain and spinal cord) as well as in adrenal gland is exactly what might be predicted for a gene whose deletion would contribute to the malignant transformation of neuroblasts. Similarly, the low (or absent) expression observed in neuroblastoma cell lines, as well as the correlation of low expression with high-risk features (1p deletion, MYCN amplification, advanced stage, unfavorable histology) in primary tumors, suggest that decreased CHD5 expression may contribute to the aggressive phenotype associated with these high-risk tumors.
We are currently pursuing the normal function of this gene in neural development, as well as possible mechanisms of homozygous deletion or inactivation in neuroblastomas with 1p deletions. To date, we have only identified one missense mutation in a neuroblastoma cell line with 1p36 deletion, suggesting that mutation is not a common mechanism of homozygous inactivation. We have shown increased expression in neuroblastoma cell lines grown in the presence of 5-azacytidine, suggesting that the remaining copy may be methylated. However, it is not clear if this is a common feature of neuroblastomas with 1p deletions or is a consequence of adaptation to growth in vitro. We are continuing to analyse this point, and the consequence of CHD5 transfection, in neuroblastoma cell lines.
Materials and methods
DNA-based bioinformatics
Draft genomic sequence from P1-artificial (PAC) clones RP11-461L11 and RP11-233K16 (GenBank Accession Numbers AC 026968 and AL 035406, respectively) were analysed with the ab initio gene prediction program Genscan (http://genes.mit.edu/ GENSCAN.html) and the sequence annotation resource Ensembl (www.ensembl.org) to identify putative coding regions. Predicted exon sequences were then used to search GenBank using BLAST (http://www.ncbi.nlm.nih.gov/ BLAST) to identify homologies and similarities to known genes and proteins. Exon/intron boundaries were determined by an alignment of the full-length CHD5 cDNA sequence with the corresponding genomic sequence (GenBank Accession NT_019265) using BLAST 2 sequences (Tatusova and Madden, 1999) . For evaluation of Genscan and Ensembl, exon sensitivity, exon specificity, whole exon, and missing exon rates were calculated as defined, as described by Reese (Reese et al., 2000) .
EST and genomic DNA alignments were performed using the genomic analysis software package MacVector version 6.5.3. (Accelrys, San Diego, CA, USA). EST and SAGE data were obtained from the National Center for Biotechnology Information at http://www.ncbi.nlm.nih.gov/SAGE/ and http://www.ncbi.nlm.nih.gov/UniGene, respectively. CpG island identification was performed with the algorithm CPG (http://www.emboss.org/). Promoter analysis was performed using TESS at the Baylor College of Medicine (http:// searchlauncher.bcm.tmc.edu/).
Protein-based bioinformatics
Protein motifs were identified by queries of the Pfam proteindomain database (http://www.sanger.ac.uk/Software/Pfam/), Interpro (http://www.ebi.ac.uk/interpro/), BLASTP, and by visual inspection of sequence alignments with additional CHD family members. Alignment of protein sequences for HsChd1, HsChd2, HsChd3, HsChd4, HsChd5, dMi-2 (Drosophila), and a predicted MmChd5 was performed using the Clustal W algorithm in MacVector. GenBank accession numbers of the identified proteins are as follows: HsChd1 (XP-004000), HsChd2 (XP-007722), HsChd3 (NP-001263), HsChd4 (NP-001264), and dMi-2 (AAD17276). The prediction of the possible mouse ortholog of the human CHD5 was performed by database searches at the NCBI using TBLASTN and BLASTN against mouse ESTs. Although a large number of homologous ESTs were likely to be the orthologs of other CHD gene family members according to the predicted protein sequences, one clone (GenBank: AK015949) was completely homologous within stretches of HsChd5 alone.
Cell lines and nucleic acid isolation
Cell line specifics, culture conditions, and DNA extraction methods for neuroblastoma cell lines CHLA-51, CHLA-79, CHLA-90, CHLA-123, CHLA-150, CHP-134, CHP-901, CHP-902R, IMR-5, KCN, KCN-R, LA-N-5, NB69, NBLS, NGP, NLF, NMB, OAN, SK-N-AS, SK-N-BE(2), SK-N-DZ, SK-N-FI, SK-N-SH, and SMS-KAN have been described previously . The primary tumors were obtained from the Children's Oncology Group (COG) tissue and nucleic acids bank, and they were selected to be broadly representative of an unselected group of patients and with similar proportions of the known high-risk features (age >1 year, INSS stages 3 and 4, MYCN amplification, 1p deletion, unfavorable histology). All studies were approved by the COG Neuroblastoma Biology Committee and by the Institutional Review Board of CHOP.
Total mRNA was isolated from cell lines using the Totally RNA s system (Ambion, Austin, TX, USA), and a panel of 15 normal tissue mRNAs was purchased from Clontech (Clontech Labs, Palo Alto, CA, USA). cDNA was generated using a Superscript II RT s Kit (Invitrogen, Carlsbad, CA, USA). PolyA + RNA was extracted from cell line RNAs using the Oligotex polyA + purification kit (Qiagen, Valencia, CA, USA).
DNA sequencing, Northern analysis, and 5 0 RACE DNA sequences for CHD5 were obtained on an Applied Biosystems Model 3700 DNA sequencer using the ABI PRISM s BigDyet Primer Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) (Maris et al., 1996) . The 5 0 end of CHD5 was obtained by sequencing of a PCR fragment amplified using the 5 0 RACE System, Version 2.0 (Invitrogen, Carlsbad, CA, USA). Primer sequences used for 5 0 RACE were 5 0 -TCATCATTGCTCCCCTCTTT for the initial amplification and 5 0 -TTCTTCCGCT-TCCCTTTACA for the second round of amplification. The mRNA sequence has been deposited in GenBank (accession number AF425231).
Real-Time RT-PCR (TaqMan)
CHD5 gene-specific primers and fluorescent probes were identified using Primer Express 5.1 and obtained from Applied Biosystems (http://www.appliedbiosystems.com/updates/oligos.html). CHD5 amplification primer sequences used were 5 0 -CCGAGATCCCAAACGGTG (residues 1443-1459) and 5 0 -CCAGTGTAGAATCCGCTGGAC (residues 1505-1525); the oligonucleotide sequence used for amplification product detection was 5 0 -CTCTGCCCGCGCTGTACTTGCC (residues 1466-1487). Primers and probes for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a ubiquitously expressed housekeeping gene multiplexed along with the candidate gene to provide an internal control and for quantification, were purchased from Applied Biosystems. Each amplification reaction contained 1X Master Mix (Applied Biosystems), 50 ng of cDNA, 5 mm GAPDH detection primer, 5 mm CHD5 detection primer, 10 mm of each GAPDH amplification primer, and 10 mm of each CHD5 amplification primer. Samples were amplified in triplicate in 20 ml reaction volumes in a 96-well format, using conditions of one cycle at 501C for 2 min; 1 cycle at 951C for 10 min; 55 cycles at 951C, for 15 s and then 601C for 1 min. Standards with known DNA concentrations were included in every run for reaction controls. Assays were performed on an ABI Prism 7700 Sequence detection system. Signals were normalized and quantified relative to GAPDH with the associated program Sequence Detector v1.7, using the comparative method.
